Published in Biotech Law Weekly, June 4th, 2004
The company reported that consolidated net sales for its first quarter 2004 increased 21% to $96.1 million, from $79.6 million for the same period in 2003.
Operating income for the quarter, including restructuring and relocation charges increased 12% to $18.1 million from $16.1 million in the comparable period in 2003, and net income for the quarter increased 4% to $11.4 million from $11.0 million in the same quarter of 2003.
Diluted earnings per share remained unchanged at $0.08, based on 148.8 million...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.